Patents by Inventor Klaus Giese
Klaus Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7279307Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.Type: GrantFiled: June 19, 2003Date of Patent: October 9, 2007Assignee: Chiron CorporationInventors: Klaus Giese, Hong Xin
-
Publication number: 20070178509Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.Type: ApplicationFiled: January 24, 2007Publication date: August 2, 2007Inventors: Hong Xin, Klaus Giese
-
Patent number: 7122373Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.Type: GrantFiled: May 13, 1999Date of Patent: October 17, 2006Assignee: Nuvelo, Inc.Inventors: Lewis T. Williams, Jaime Escobedo, Michael A. Innis, Pablo Dominguez Garcia, Julie Sudduth-Klinger, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C. Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Birgit Stache-Crain
-
Patent number: 6964868Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.Type: GrantFiled: January 28, 1999Date of Patent: November 15, 2005Assignee: Nuvelo, Inc.Inventors: Lewis T. Williams, Jaime Escobedo, Michael A. Innis, Pablo Dominguez Garcia, Julie Sudduth-Klinger, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C. Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Birgit Stache-Crain
-
Publication number: 20050227917Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.Type: ApplicationFiled: February 12, 2004Publication date: October 13, 2005Inventors: Lewis Williams, Jaime Escobedo, Michael Innis, Pablo Garcia, Julie Sudduth-Klinger, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia Kennedy, David Pot, Altaf Kassam, George Lamson, Zhijun He, Elizabeth Scott, Guozhong Zhang, Theresa May, Doreen Sakamoto, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee Jones, Birgit Stache-Crain
-
Publication number: 20050043263Abstract: The present invention is related to the use of a ribonucleic acid for the manufacture of a medicament, wherein the ribonucleic acid comprises a double-stranded structure and the double-stranded structure comprises a first and a second strand, wherein the first strand comprises a first stretch of contiguous nucleotides and the second strand comprises a second stretch of contiguous nucleotides, wherein the first stretch is not complementary to a nucleic acid, preferably a mRNA, of a cell of an organism to be treated with said medicament and/or wherein the second stretch is different from a nucleic acid, preferably a mRNA of a cell of an organism to be treated with said medicament.Type: ApplicationFiled: June 28, 2004Publication date: February 24, 2005Applicant: Atugen AGInventors: Klaus Giese, Joerg Kaufmann
-
Publication number: 20040180351Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 5, 2003Publication date: September 16, 2004Applicant: Atugen AGInventors: Klaus Giese, Jorg Kaufmann, Anke Klippel-Giese
-
Publication number: 20040076997Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.Type: ApplicationFiled: June 19, 2003Publication date: April 22, 2004Applicant: Chiron CorporationInventors: Hong Xin, Klaus Giese
-
Patent number: 6635748Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.Type: GrantFiled: December 17, 1998Date of Patent: October 21, 2003Assignee: Chiron CorporationInventors: Hong Xin, Klaus Giese
-
Publication number: 20030158109Abstract: Gene sequences as shown in SEQ ID NOS: 1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS: 1-85, or a substantial portion thereof.Type: ApplicationFiled: September 5, 2002Publication date: August 21, 2003Inventor: Klaus Giese
-
Publication number: 20030135033Abstract: The present invention is related to a compound, preferably 14 to 30 nucleobases, preferably 17 to 23 nucleobases and more preferably 17 to 21 nucleobases in length, targeted to a nucleic acid whereby the nucleic acid is heterogeneous nuclear RNA (hnRNA).Type: ApplicationFiled: January 6, 2003Publication date: July 17, 2003Inventors: Anke Klippel-Giese, Jorg Kaufmann, Klaus Giese
-
Patent number: 6468790Abstract: Gene sequences as shown in SEQ ID NOS:1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-85, or a substantial portion thereof.Type: GrantFiled: November 13, 2000Date of Patent: October 22, 2002Assignee: Chiron CorporationInventor: Klaus Giese
-
Publication number: 20020076735Abstract: The invention provides materials and methods for determining the metastatic potential of a cell and for identifying cancerous cells by determining the presence or absence of one or more expression products of at least one gene that is differentially expressed between normal cells, nonmetastatic cells, cells of low metastatic potential, and cells of high metastatic potential.Type: ApplicationFiled: May 10, 2001Publication date: June 20, 2002Inventors: Lewis T. Williams, Jaime Escobedo, Michael A. Innis, Pablo Dominguez Garcia, Julie Sudduth-Klinger, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C. Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Birgit Stache-Crain
-
Publication number: 20020068278Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.Type: ApplicationFiled: December 17, 1998Publication date: June 6, 2002Inventors: KLAUS GIESE, HONG XIN
-
Publication number: 20020009739Abstract: Gene sequences as shown in SEQ ID NOS: 1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS: 1-85, or a substantial portion thereof.Type: ApplicationFiled: April 6, 2001Publication date: January 24, 2002Inventor: Klaus Giese
-
Patent number: 5747338Abstract: A collision construct is provided that contains a first regulatory sequence containing a first promoter linked to a reporter gene which is also linked to a second regulatory sequence containing a second promoter such that the reporter gene is under regulatory control of the first promoter. The direction of transcription under the first promoter is opposite the direction of transcription under the second promoter and activation of the second promoter interferes with reporter gene activity. The collision construct is used to screen inhibitors of the second regulatory sequence and the second promoter whereby a functional inhibitor causes an enhanced signal of the reporter gene. Vectors, host cells and kits containing the collision construct are provided, as well as methods for producing the collision construct, the vectors and host cells, and methods for screening candidate inhibitors for their ability to inhibit target promoter activities.Type: GrantFiled: September 25, 1996Date of Patent: May 5, 1998Assignee: Chiron CorporationInventors: Klaus Giese, Jaime Escobedo
-
Patent number: 5291366Abstract: This surge voltage arrester has two connecting fittings (1, 2) which are braced with respect to one another. At least one pellet (7) consisting of varistor material is clamped in between the connecting fittings (1, 2).It is intended to create a surge voltage arrester which can be produced using simple means and which, in addition, can be cast around in a simple manner. This is achieved in that at least two insulating clamping elements, which are arranged symmetrically, are provided for bracing the connecting fittings (1, 2). The clamping elements, the at least one pellet (7) and, partially, the connecting fittings (1, 2) have insulating plastic material cast around them to form a monolithic block.Type: GrantFiled: October 26, 1992Date of Patent: March 1, 1994Assignee: Asea Brown Boveri Ltd.Inventors: Klaus Giese, Walter Nydegger, Walter Schmidt
-
Patent number: 4796283Abstract: A device for counting the overvoltage surges discharged by a gapless overvoltage arrester contains a sensing head and a counting mechanism which follows the sensing head. In the sensing head, the discharge current carried by the overvoltage arrester in a ground return line during the occurrence of an overvoltage surge is detected. The counting mechanism records an overvoltage surge as soon as the discharge current exceeds a threshold value. During this process, an effective connection between the sensing head and a counter is established for a brief time by means of a switch. This device is intended to be characterized, with a high counting accuracy, by a dead time which is independent of the components used. This is achieved by the measure that the switch is followed by a threshold detector which responds above the threshold value of the discharge current.Type: GrantFiled: March 18, 1987Date of Patent: January 3, 1989Assignee: BBC Brown, Boveri Ltd.Inventors: Kurt Brunner, Rudolf Fischer, Klaus Giese